These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 29286614)

  • 21. p 53 codon 72 polymorphism in stomach and colorectal adenocarcinomas in Iranian patients.
    Mojtahedi Z; Haghshenas MR; Hosseini SV; Fattahi MJ; Ghaderi A
    Indian J Cancer; 2010; 47(1):31-4. PubMed ID: 20071787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship Between Genetic Polymorphisms in Cell Cycle Regulatory Gene TP53 and Polycystic Ovarian Syndrome: A Case-Control Study and In Silico Analyses.
    Biglari-Zadeh G; Sargazi S; Mohammadi M; Ghasemi M; Majidpour M; Saravani R; Mirinejad S
    Biochem Genet; 2023 Oct; 61(5):1827-1849. PubMed ID: 36856940
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single-strand conformational polymorphism analysis of a common single nucleotide variation in WRAP53 gene, rs2287499, and evaluating its association in relation to breast cancer risk and prognosis among Iranian-Azeri population.
    Sedaie Bonab A; Pouladi N; Hosseinpourfeizi MA; Ravanbakhsh Gavgani R; Dehghan R; Azarfam P; Montazeri V; Fakhrjou A
    Med Oncol; 2014 Sep; 31(9):168. PubMed ID: 25134915
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TP53 codon 72 and intron 3 polymorphisms and mutational status in gastric cancer: an association with tumor onset and prognosis.
    Neves Filho EH; Cordeiro DE; Vieira AP; Rabenhorst SH
    Pathobiology; 2012; 79(6):323-8. PubMed ID: 22688387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TP53 Pro47Ser and Arg72Pro polymorphisms and colorectal cancer predisposition in an ethnic Kashmiri population.
    Sameer AS; Shah ZA; Syeed N; Banday MZ; Bashir SM; Bhat BA; Siddiqi MA
    Genet Mol Res; 2010 Apr; 9(2):651-60. PubMed ID: 20449797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms in pancreatic ductal adenocarcinoma.
    Hori Y; Miyabe K; Yoshida M; Nakazawa T; Hayashi K; Naitoh I; Shimizu S; Kondo H; Nishi Y; Umemura S; Kato A; Ohara H; Inagaki H; Joh T
    PLoS One; 2015; 10(3):e0118829. PubMed ID: 25734904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A candidate intronic
    Sadeghi H; Nazemalhosseini-Mojarad E; Piltan S; Fazeli E; Moradi Y; Amin-Beidokhti M; Yassaee VR; Aghdaei HA; Zali MR; Mirfakhraie R
    Biomark Med; 2020 Jan; 14(1):23-29. PubMed ID: 31802707
    [No Abstract]   [Full Text] [Related]  

  • 28. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
    Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
    BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of the p53 codon 72 polymorphism with clinicopathological characteristics of colorectal cancer through mRNA analysis.
    De Oliveira LP; López I; Dos Santos EM; Tucci P; Marín M; Soares FA; Rossi BM; Coudry Rde A
    Oncol Rep; 2014 Mar; 31(3):1396-406. PubMed ID: 24366026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The rs6983267 SNP is associated with MYC transcription efficiency, which promotes progression and worsens prognosis of colorectal cancer.
    Takatsuno Y; Mimori K; Yamamoto K; Sato T; Niida A; Inoue H; Imoto S; Kawano S; Yamaguchi R; Toh H; Iinuma H; Ishimaru S; Ishii H; Suzuki S; Tokudome S; Watanabe M; Tanaka J; Kudo SE; Mochizuki H; Kusunoki M; Yamada K; Shimada Y; Moriya Y; Miyano S; Sugihara K; Mori M
    Ann Surg Oncol; 2013 Apr; 20(4):1395-402. PubMed ID: 22976378
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between TP53 and interleukin-6 gene variants and the risk of types 1 and 2 diabetes mellitus development in the Kermanshah province.
    Haghnazari L; Sabzi R
    J Med Life; 2021; 14(1):37-44. PubMed ID: 33767783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TP53 codon 72 polymorphism and breast cancer risk in Bangladeshi population.
    Hossain A; Murshid GMM; Zilani MNH; Islam F; Sultana R; Sultana T; Hossain MG; Rahman MM
    Breast Cancer; 2017 Jul; 24(4):571-578. PubMed ID: 27837441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interaction between TP53 and XRCC1 increases susceptibility to cervical cancer development: a case control study.
    Liu GC; Zhou YF; Su XC; Zhang J
    BMC Cancer; 2019 Jan; 19(1):24. PubMed ID: 30616520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry.
    Yurgelun MB; Masciari S; Joshi VA; Mercado RC; Lindor NM; Gallinger S; Hopper JL; Jenkins MA; Buchanan DD; Newcomb PA; Potter JD; Haile RW; Kucherlapati R; Syngal S;
    JAMA Oncol; 2015 May; 1(2):214-21. PubMed ID: 26086041
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Yazdanpanahi N; Salehi R; Kamali S
    J Cancer Res Ther; 2018; 14(3):614-618. PubMed ID: 29893328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TP53 polymorphisms in gliomas from Indian patients: Study of codon 72 genotype, rs1642785, rs1800370 and 16 base pair insertion in intron-3.
    Jha P; Jha P; Pathak P; Chosdol K; Suri V; Sharma MC; Kumar G; Singh M; Mahapatra AK; Sarkar C
    Exp Mol Pathol; 2011 Apr; 90(2):167-72. PubMed ID: 21115003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. p53 signaling pathway polymorphisms associated to recurrent pregnancy loss.
    Fraga LR; Dutra CG; Boquett JA; Vianna FS; Gonçalves RO; Paskulin DD; Costa OL; Ashton-Prolla P; Sanseverino MT; Schuler-Faccini L
    Mol Biol Rep; 2014 Mar; 41(3):1871-7. PubMed ID: 24435975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of TP53 codon 72 and MDM2 promoter 309 allelic dosage in a Moroccan population with hepatocellular carcinoma.
    Ezzikouri S; Essaid El Feydi A; Afifi R; Benazzouz M; Hassar M; Pineau P; Benjelloun S
    Int J Biol Markers; 2011; 26(4):229-33. PubMed ID: 22180176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Germ-line genetic variation of TP53 in osteosarcoma.
    Savage SA; Burdett L; Troisi R; Douglass C; Hoover RN; Chanock SJ;
    Pediatr Blood Cancer; 2007 Jul; 49(1):28-33. PubMed ID: 17096406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Effect of
    Alhadheq AM; Purusottapatnam Shaik J; Alamri A; Aljebreen AM; Alharbi O; Almadi MA; Alhadeq F; Azzam NA; Semlali A; Alanazi M; Bazzi MD; Reddy Parine N
    Dis Markers; 2016; 2016():8289293. PubMed ID: 27746584
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.